On August 7, KEYMED BIO-B rose 5.46% in regular trading, trading at HK$81.2/share, with turnover of HK$63.72 million.

The rally was driven by concentrated institutional accumulation. Data disclosed on August 6 showed Orient Securities increased its stake by approximately 203,500 shares on July 30 at an average price of HK$72.88, lifting its holding ratio from 4.98% to 5.05%, triggering the disclosure threshold. Earlier, Goldman Sachs acquired 287,500 shares on July 13, raising its stake to 5.00%.

Institutional buying resonated with multiple pipeline developments. CMG901, an ADC co-developed with AstraZeneca targeting CLDN18.2, achieved positive Phase III topline results in late July, demonstrating statistically significant overall survival improvement in advanced gastric cancer. Additionally, CM512, the company's TSLP/IL-13 bispecific antibody, received Breakthrough Therapy Designation for chronic rhinosinusitis with nasal polyps in late July. The company also issued a positive profit alert projecting H1 net profit of no less than RMB 1.2 billion, reversing a year-earlier loss of approximately RMB 79 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)